Background Direct oral anticoagulants (DOACs) are the treatment of choice for most patients
with atrial fibrillation and/or noncancer-associated venous thromboembolic disease …

The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …

Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared
to vitamin K antagonists (VKAs) for the prevention and treatment of venous …

Background: Direct oral anticoagulants (DOACs) are prescribed for anticoagulation in
patients with atrial fibrillation and venous thromboembolic disease. Fixed doses are …

For decades, oral anticoagulation has been based on vitamin K antagonist such as warfarin,
which requires pharmacodynamic (PD) drug monitoring to guide the therapy. The drug effect …

In certain clinical situations, it is necessary to determine whether clinically relevant plasma
levels of direct oral anticoagulants (DOACs) are present. We examined whether qualitative …

Direct oral anticoagulants (DOACs) are now widely used in various thromboembolic
diseases. Although routine therapeutic drug monitoring is not required, cumulative evidence …

Background: Detection of new oral anticoagulant (NOAC) levels by screening, special and
global tests, and liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS) is …

Abstract Use of Direct Oral Anticoagulants (DOACs) is continuously increasing for clinical
application. The first product released was Dabigatran, which was proposed for many …

Introduction Several specific assays are commercially available to determine dabigatran
anticoagulant activity. Aims of this multicenter and multiplatform study were to compare five …